First-in-Class Epigenetic Silencer TUNE-401 Shows Positive Phase 1b/2a Proof-of-Concept Data for Hepatitis B at EASL 2026
Initial clinical data demonstrates deep and durable antiviral activity, including direct silencing of cccDNA, offering a potential pathway to a finite cure for HBV patients — with significant implications for…
